within Pharmacolibrary.Drugs.ATC.L;

model L01EB08
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.59,
    Cl             = 0.26166666666666666,
    adminDuration  = 600,
    adminMass      = 0.125,
    adminCount     = 1,
    Vd             = 0.0513,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.008616666666666667,
    Tlag           = 10.200000000000001
  );

  annotation(Documentation(
    info ="<html><body><p>Icotinib is an orally administered, small-molecule tyrosine kinase inhibitor that selectively inhibits the epidermal growth factor receptor (EGFR). It is used primarily for the treatment of non-small cell lung cancer (NSCLC) and is approved in China for this indication.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported in Chinese adult patients with advanced non-small cell lung cancer after oral administration of icotinib tablets.</p><h4>References</h4><ol><li><p>Hu, P, et al., &amp; Jiang, J (2015). Development of population pharmacokinetics model of icotinib with non-linear absorption characters in healthy Chinese volunteers to assess the CYP2C19 polymorphism and food-intake effect. <i>European journal of clinical pharmacology</i> 71(7) 843–850. DOI:<a href=&quot;https://doi.org/10.1007/s00228-015-1864-5&quot;>10.1007/s00228-015-1864-5</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/25995169/&quot;>https://pubmed.ncbi.nlm.nih.gov/25995169</a></p></li><li><p>Liu, D, et al., &amp; Hu, P (2014). Clinical pharmacokinetics of Icotinib, an anti-cancer drug: evaluation of dose proportionality, food effect, and tolerability in healthy subjects. <i>Cancer chemotherapy and pharmacology</i> 73(4) 721–727. DOI:<a href=&quot;https://doi.org/10.1007/s00280-014-2398-8&quot;>10.1007/s00280-014-2398-8</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/24488324/&quot;>https://pubmed.ncbi.nlm.nih.gov/24488324</a></p></li><li><p>Ruan, CJ, et al., &amp; Hu, P (2012). Effect of the CYP2C19 genotype on the pharmacokinetics of icotinib in healthy male volunteers. <i>European journal of clinical pharmacology</i> 68(12) 1677–1680. DOI:<a href=&quot;https://doi.org/10.1007/s00228-012-1288-4&quot;>10.1007/s00228-012-1288-4</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/22585284/&quot;>https://pubmed.ncbi.nlm.nih.gov/22585284</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end L01EB08;
